OncoMatch/Clinical Trials/NCT05423262
A Study of TRK-950 in Patients With Advanced Solid Tumors
Is NCT05423262 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for solid tumor.
Treatment: TRK-950 · TRK-950 · TRK-950 · Nivolumab · TRK-950 — Part 1 • To determine the safety and tolerability of TRK-950 in patients with advanced solid tumors Part 2 • To determine the safety and tolerability of TRK-950 in combination with nivolumab(NIVO) in patients with advanced solid tumors eligible for NIVO therapy Part 3 • To determine the efficacy of TRK-950 in patients with advanced/recurrent unresectable melanoma, who received prior chemotherapy with dacarbazine(DTIC) and for whom no standard therapy exists
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Melanoma
Prior therapy
Must have received: chemotherapy (dtic)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify